{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:22:13Z","timestamp":1787026933909,"version":"build-2736575974"},"reference-count":245,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:p>Hematologic malignancies pose significant global health burdens, with programmed cell death protein-1 (PD-1)\/programmed cell death ligand 1 (PD-L1) inhibitors revolutionizing treatment in subtypes like classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBCL), achieving high objective response rates (ORR). However, efficacy varies widely, with limited success in multiple myeloma (&amp;lt; 10% ORR) and leukemias, underscoring the need for better predictors beyond tumor-intrinsic biomarkers. This review highlights pre-treatment endocrine\u2013nutritional signatures as key host factors influencing immunotherapy outcomes. Dysregulated hormones (cortisol, thyroid, sex steroids, insulin\/insulin-like growth factor-1, adipokines) and nutritional status (vitamin D, zinc, protein-energy malnutrition, iron metabolism) modulate T-cell exhaustion, myeloid suppression, and tumor microenvironment dynamics, often leading to resistance. Evidence from cohorts shows hypercortisolism, hypothyroidism, insulin resistance, vitamin D deficiency, and hypoalbuminemia correlate with inferior ORR, progression-free survival, and overall survival, while thyroid immune-related adverse events and moderate obesity predict benefit. In hematologic contexts, marrow infiltration exacerbates these imbalances, explaining heterogeneous responses. Integrated signatures (e.g., Glasgow Prognostic Score, Prognostic Nutritional Index) offer superior prognostic value, enabling targeted interventions like vitamin D supplementation, metformin, or nutritional support to enhance immune checkpoint inhibitor efficacy. Mechanistic insights reveal convergence on mTOR\/IFN-\u03b3 pathways and microbiome modulation. Translating these to clinical panels could personalize immunotherapy, addressing gaps in hematologic malignancies literature and improving outcomes in relapsed\/refractory settings.<\/jats:p>","DOI":"10.3389\/fnut.2025.1753660","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:23:32Z","timestamp":1770269012000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Pre-treatment endocrine\u2013nutritional signatures predict clinical benefit from PD-1\/PD-L1 blockade in hematologic malignancies"],"prefix":"10.3389","volume":"12","author":[{"given":"Ningjing","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Neurology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guan","sequence":"additional","affiliation":[{"name":"Diagnostic Laboratory for Hematology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","first-page":"543","volume-title":"Epidemiology of hematologic malignancies. Pathology and epidemiology of cancer.","author":"Batista","year":"2016"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.","volume":"99","author":"Ansell","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","article-title":"Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study.","volume":"36","author":"Gettinger","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6266","DOI":"10.1182\/bloodadvances.2023010334","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.","volume":"7","author":"Ansell","year":"2023","journal-title":"Blood Adv"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1643421","DOI":"10.3389\/fimmu.2025.1643421","article-title":"Advances in PD-1\/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives.","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41375-020-0868-z","article-title":"Isatuximab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma patients with renal impairment: icaria-mm subgroup analysis.","volume":"35","author":"Dimopoulos","year":"2021","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome.","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1485849","DOI":"10.3389\/fonc.2024.1485849","article-title":"Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy.","volume":"14","author":"Ge","year":"2024","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/s41467-023-38360-5","article-title":"Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer.","volume":"14","author":"Sun","year":"2023","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"643298","DOI":"10.3389\/fimmu.2021.643298","article-title":"Immunomodulation of t helper cells by tumor microenvironment in oral cancer is associated with CCR8 expression and rapid membrane Vitamin D signaling pathway.","volume":"12","author":"Fraga","year":"2021","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy.","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle.","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure.","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma.","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL.","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma.","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/S2152-2650(21)01854-1","article-title":"HL-398: five-year overall survival from the CheckMate 205 study of nivolumab for relapsed or refractory (R\/R) classical Hodgkin lymphoma (cHL).","volume":"21","author":"Ansell","year":"2021","journal-title":"Clin Lymphoma Myeloma Leukemia."},{"key":"B22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma.","volume":"142","author":"Armand","year":"2023","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.HS9.0000561564.12955.95","article-title":"S821 Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical hodgkin lymphoma: 2-year extended follow-up from cohort d of the phase 2 checkmate 205 study.","volume":"3","author":"Domingo-Dom\u00e8nech","year":"2019","journal-title":"HemaSphere."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood.2022019340","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.","volume":"142","author":"Zinzani","year":"2021","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","article-title":"Nivolumab combined with brentuximab vedotin for R\/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.","volume":"7","author":"Zinzani","year":"2023","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-Cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study.","volume":"37","author":"Ansell","year":"2019","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation.","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/bloodadvances.2023012145","article-title":"Brentuximab vedotin and chemotherapy in relapsed\/refractory Hodgkin lymphoma: a propensity score-matched analysis.","volume":"8","author":"Driessen","year":"2024","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/bloodadvances.2021006240","article-title":"Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Blood Adv"},{"key":"B32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4).","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study.","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1182\/bloodadvances.2022008460","article-title":"Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed\/refractory multiple myeloma.","volume":"7","author":"Nishihori","year":"2023","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.clml.2024.05.014","article-title":"Nivolumab, pomalidomide, and elotuzumab combination regimens for treatment of relapsed and refractory multiple myeloma: results from the phase 3 CheckMate 602 study.","volume":"24","author":"Oriol","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma.","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","article-title":"Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions.","volume":"11","author":"Caraccio","year":"2020","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1182\/bloodadvances.2024015200","article-title":"PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome.","volume":"9","author":"Magenau","year":"2025","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","article-title":"PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.","volume":"5","author":"Kong","year":"2015","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41375-024-02175-0","article-title":"Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.","volume":"38","author":"Shimony","year":"2024","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma.","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17588359241273053","DOI":"10.1177\/17588359241273053","article-title":"Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies.","volume":"16","author":"Jeong","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"107553","DOI":"10.1016\/j.intimp.2021.107553","article-title":"Expression of PD-L1 in EBV-associated malignancies.","volume":"95","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/sci.2017.03.04","article-title":"Immune checkpoint blockade for hematologic malignancies: a review.","volume":"4","author":"Pianko","year":"2017","journal-title":"Stem Cell Investig"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1007\/s40265-017-0796-z","article-title":"Anti-PD-1 antibodies as a therapeutic strategy in classical hodgkin lymphoma.","volume":"77","author":"Jain","year":"2017","journal-title":"Drugs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40164-025-00705-9","article-title":"Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer.","volume":"14","author":"Wang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.46235\/1028-7221-17074-TTQ","article-title":"Towards the question of the theory neuro-immuno-endocrine system.","author":"Chereshnev","year":"2025","journal-title":"Russian J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1210\/edrv-17-1-64","article-title":"Immune-neuro-endocrine interactions: facts and hypotheses.","volume":"17","author":"Besedovsky","year":"1996","journal-title":"Endocr Rev"},{"key":"B51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ccell.2020.09.004","article-title":"Immunometabolic interplay in the tumor microenvironment.","volume":"39","author":"Kaymak","year":"2021","journal-title":"Cancer Cell"},{"key":"B52","first-page":"747","article-title":"Immunotherapy through the years.","volume":"8","author":"Eno","year":"2017","journal-title":"J Adv Pract Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1381250","DOI":"10.3389\/fonc.2024.1381250","article-title":"The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis.","volume":"14","author":"Zhao","year":"2024","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/NIB-2011-007","article-title":"The immuno-endocrine system: hormones, receptors and endocrine function of immune cells. The packed-transport theory.","volume":"1","author":"Csaba","year":"2011","journal-title":"Adv Neuroimmune Biol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders.","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/ar4484","article-title":"Interaction of the endocrine system with inflammation: a function of energy and volume regulation.","volume":"16","author":"Straub","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41593-019-0370-y","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41419-025-07636-7","article-title":"Addition of metformin to anti-PD-1\/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients.","volume":"16","author":"Amato","year":"2025","journal-title":"Cell Death Dis"},{"key":"B60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T cell dysfunction and exhaustion in cancer.","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous glucocorticoid signaling regulates CD8+ T cell differentiation and development of dysfunction in the tumor microenvironment.","volume":"53","author":"Acharya","year":"2020","journal-title":"Immunity"},{"key":"B62","doi-asserted-by":"publisher","first-page":"19896","DOI":"10.1074\/jbc.RA119.010379","article-title":"Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells.","volume":"294","author":"Maeda","year":"2019","journal-title":"J Biol Chem"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1500108","DOI":"10.1080\/2162402X.2018.1500108","article-title":"Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system.","volume":"7","author":"Maxwell","year":"2018","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids.","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J Exp Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e004150","DOI":"10.1136\/jitc-2021-004150","article-title":"Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.","volume":"11","author":"Martins Nascentes Melo","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/thy.2010.0429","article-title":"Thyroid hormones as modulators of immune activities at the cellular level.","volume":"21","author":"De Vito","year":"2011","journal-title":"Thyroid."},{"key":"B68","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1096\/fj.14-262246","article-title":"TAS2R bitter taste receptors regulate thyroid function.","volume":"29","author":"Clark","year":"2015","journal-title":"FASEB J"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e3704","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid Immune-related adverse events following immune checkpoint inhibitor treatment.","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e240064","DOI":"10.1530\/ERC-24-0064","article-title":"Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.","volume":"31","author":"Garc\u00eda-Go\u00f1i","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00262-020-02802-6","article-title":"Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study.","volume":"70","author":"Thuillier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B72","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1158\/1078-0432.CCR-19-0137","article-title":"Sex hormones and anticancer immunity.","volume":"25","author":"\u00d6zdemir","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/jnci\/djz094","article-title":"Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis.","volume":"111","author":"Conforti","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy.","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"key":"B76","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2017.10.002","article-title":"Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-na\u00efve prostate cancer: a systematic review and network meta-analysis.","volume":"73","author":"Wallis","year":"2018","journal-title":"Eur Urol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1210297","DOI":"10.3389\/fonc.2023.1210297","article-title":"Role of sex and sex hormones in PD-L1 expression in NSCLC: clinical and therapeutic implications.","volume":"13","author":"Rodriguez-Lara","year":"2023","journal-title":"Front Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1356321","DOI":"10.3389\/fimmu.2024.1356321","article-title":"Manipulating the tumor immune microenvironment to improve cancer immunotherapy: igf1r, a promising target.","volume":"15","author":"Pellegrino","year":"2024","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"31072","DOI":"10.1038\/srep31072","article-title":"Metformin enhances the therapy effects of Anti-IGF-1R mAb figitumumab to NSCLC.","volume":"6","author":"Cao","year":"2016","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12079-021-00648-w","article-title":"Targeting of the tumor immune microenvironment by metformin.","volume":"16","author":"Wu","year":"2022","journal-title":"J Cell Commun Signal"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1158\/1078-0432.CCR-22-3116","article-title":"Type 2 diabetes mellitus and efficacy outcomes from immune checkpoint blockade in patients with cancer.","volume":"29","author":"Cortellini","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade.","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccell.2025.01.004","article-title":"Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity.","volume":"43","author":"Braun","year":"2025","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/s41586-024-07529-3","article-title":"Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.","volume":"630","author":"Bader","year":"2024","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1475-2891-9-69","article-title":"Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature.","volume":"9","author":"Gupta","year":"2010","journal-title":"Nutr J"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1148786","DOI":"10.3389\/fonc.2023.1148786","article-title":"Prognostic role of C-reactive protein to albumin ratio in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.","volume":"13","author":"Dai","year":"2023","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.nutres.2025.08.003","article-title":"Higher serum vitamin D concentration and supplementation were associated with improved survival outcomes and treatment response in cancer patients receiving immunotherapy: a systematic review and meta-analysis.","volume":"141","author":"Yang","year":"2025","journal-title":"Nutr Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1126\/science.adp1309","article-title":"Microbes and vitamin D aid immunotherapy.","volume":"384","author":"Franco","year":"2024","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/imm.13696","article-title":"Serum vitamin D deficiency is associated with increased risk of \u03b3\u03b4 T cell exhaustion in HBV-infected patients.","volume":"171","author":"Li","year":"2024","journal-title":"Immunology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.1017\/S0007114507832971","article-title":"Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses.","volume":"98","author":"Maggini","year":"2007","journal-title":"Br J Nutr"},{"key":"B91","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/cells10020303","article-title":"Iron metabolism in the tumor microenvironment-implications for anti-cancer immune response.","volume":"10","author":"Sacco","year":"2021","journal-title":"Cells"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1186\/s12885-023-11620-9","article-title":"Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer.","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e0326057","DOI":"10.1371\/journal.pone.0326057","article-title":"Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers.","volume":"20","author":"Wang","year":"2025","journal-title":"PLoS One"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/nu10091203","article-title":"Selenium, selenoproteins, and immunity.","volume":"10","author":"Avery","year":"2018","journal-title":"Nutrients"},{"key":"B95","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2016.09.031","article-title":"L-arginine modulates T Cell metabolism and enhances survival and anti-tumor activity.","volume":"167","author":"Geiger","year":"2016","journal-title":"Cell."},{"key":"B96","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance.","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","article-title":"Impact of oncogenic pathways on evasion of antitumour immune responses.","volume":"18","author":"Spranger","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/imr.12849","article-title":"Obesity and CD8 T cell metabolism: implications for anti-tumor immunity and cancer immunotherapy outcomes.","volume":"295","author":"Turbitt","year":"2020","journal-title":"Immunol Rev"},{"key":"B99","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response.","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1081790","DOI":"10.3389\/fimmu.2023.1081790","article-title":"Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.","volume":"14","author":"Cui","year":"2023","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fendo.2019.00350","article-title":"Thyroid hormone action on innate immunity.","volume":"10","author":"Montesinos","year":"2019","journal-title":"Front Endocrinol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cytogfr.2019.11.006","article-title":"Insulin as an immunomodulatory hormone.","volume":"52","author":"van Niekerk","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B105","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids.","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications.","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.","volume":"14","author":"Di Dalmazi","year":"2019","journal-title":"Expert Rev Endocrinol Metab"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"71","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B112","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1089\/thy.2019.0726","article-title":"Overt Thyroid dysfunction and anti-thyroid antibodies predict response to anti-PD-1 immunotherapy in cancer patients.","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid."},{"key":"B113","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with Anti-PD-1 therapy for advanced non-small cell lung cancer.","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"e1375642","DOI":"10.1080\/2162402X.2017.1375642","article-title":"Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer.","volume":"7","author":"Kim","year":"2018","journal-title":"Oncoimmunology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis.","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B117","doi-asserted-by":"crossref","DOI":"10.1109\/ACCESS.2024.3503438","volume-title":"A computational study of efficient combinations of FDA-approved drugs and dietary supplements in endometrial cancer.","author":"Mondal","year":"2024"},{"key":"B118","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/1078-0432.CCR-22-2812","article-title":"Phase I study of androgen deprivation therapy in combination with anti-PD-1 in melanoma patients pretreated with anti-PD-1.","volume":"29","author":"Robert","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/s12967-021-03134-4","article-title":"Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab.","volume":"19","author":"De Filippi","year":"2021","journal-title":"J Transl Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1550702","DOI":"10.3389\/fendo.2025.1550702","article-title":"Cemiplimab and diabetic ketoacidosis: a case report of a rare endocrinopathy associated with immune checkpoint inhibitors.","volume":"16","author":"Arecco","year":"2025","journal-title":"Front Endocrinol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"102044","DOI":"10.1016\/j.eclinm.2023.102044","article-title":"Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.","volume":"61","author":"Bersanelli","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B122","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.canlet.2015.01.007","article-title":"Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1\/2 phosphorylation and p38 dephosphorylation.","volume":"359","author":"Huang","year":"2015","journal-title":"Cancer Lett"},{"key":"B123","doi-asserted-by":"publisher","first-page":"993","DOI":"10.7150\/thno.104872","article-title":"Metformin-based nanomedicines for reprogramming tumor immune microenvironment.","volume":"15","author":"Liu","year":"2025","journal-title":"Theranostics"},{"key":"B124","doi-asserted-by":"publisher","first-page":"112475","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep"},{"key":"B125","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s00262-023-03522-3","article-title":"Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.","volume":"72","author":"Bersanelli","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B126","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.3390\/ijms24065739","article-title":"Erythrocytes functionality in SARS-CoV-2 infection: potential link with Alzheimer\u2019s disease.","volume":"24","author":"Kosenko","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B127","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CJI.0000000000000469","article-title":"Vitamin D status is associated with immune checkpoint inhibitor efficacy and immune-related adverse event severity in lung cancer patients: a prospective cohort study.","volume":"46","author":"You","year":"2023","journal-title":"J Immunother"},{"key":"B128","doi-asserted-by":"publisher","first-page":"937476","DOI":"10.3389\/fimmu.2022.937476","article-title":"Vitamin D metabolism pathway polymorphisms are associated with efficacy and safety in patients under anti-PD-1 inhibitor therapy.","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","article-title":"Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.","volume":"32","author":"Bittenbring","year":"2014","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer.","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e009734","DOI":"10.1136\/jitc-2024-009734","article-title":"Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade.","volume":"13","author":"Alden","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B132","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9579","volume-title":"Association of baseline body mass index (BMI) with response and survival in patients (Pts) with advanced melanoma (MEL) receiving PD-1 inhibitors.","author":"Hemadri","year":"2019"},{"key":"B133","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/ijms24043994","article-title":"Fat loss in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitors.","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B134","doi-asserted-by":"publisher","first-page":"38422","DOI":"10.1038\/s41598-025-22288-5","article-title":"IGF-1 regulates cancer cell immune evasion in prostate cancer.","volume":"15","author":"Nandakumar","year":"2025","journal-title":"Sci Rep"},{"key":"B135","doi-asserted-by":"publisher","first-page":"11244","DOI":"10.1038\/s41598-024-61150-y","article-title":"Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.","volume":"14","author":"Leek","year":"2024","journal-title":"Sci Rep"},{"key":"B136","doi-asserted-by":"publisher","first-page":"823087","DOI":"10.3389\/fnut.2022.823087","article-title":"Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"9","author":"Ni","year":"2022","journal-title":"Front Nutr"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","article-title":"The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"9","author":"Guven","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1038118","DOI":"10.3389\/fnut.2022.1038118","article-title":"Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors.","volume":"9","author":"Sun","year":"2022","journal-title":"Front Nutr"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e41087","DOI":"10.1097\/MD.0000000000041087","article-title":"Association of prognostic nutritional index with long-term survival in lung cancer receiving immune checkpoint inhibitors: a meta-analysis.","volume":"103","author":"Wang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"B140","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/jca.55322","article-title":"Intratumoral treatment with chemotherapy and immunotherapy for NSCLC with EBUS-TBNA 19G.","volume":"12","author":"Zarogoulidis","year":"2021","journal-title":"J Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"6743126","DOI":"10.1155\/2022\/6743126","article-title":"Prognostic nutritional index predicts outcome of PD-L1 negative and MSS advanced cancer treated with PD-1 inhibitors.","volume":"2022","author":"Zhang","year":"2022","journal-title":"Biomed Res Int"},{"key":"B142","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3390\/jcm8040450","article-title":"Association of sarcopenia with and efficacy of anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer.","volume":"8","author":"Nishioka","year":"2019","journal-title":"J Clin Med"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/jcsm.12623","article-title":"lncMGPF is a novel positive regulator of muscle growth and regeneration.","volume":"11","author":"Lv","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B145","doi-asserted-by":"publisher","first-page":"111345","DOI":"10.1016\/j.nut.2021.111345","article-title":"Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review and meta-analysis.","volume":"90","author":"Deng","year":"2021","journal-title":"Nutrition"},{"key":"B146","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/intimm\/dxab074","article-title":"Immune discrimination of the environmental spectrum through C-type lectin receptors.","volume":"33","author":"Torigoe","year":"2021","journal-title":"Int Immunol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e211839","DOI":"10.1001\/jamanetworkopen.2021.1839","article-title":"Hyperprogression in patients with cancer receiving immune checkpoint inhibitors.","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B148","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1186\/s12885-020-07206-4","article-title":"Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2147\/CMAR.S476150","article-title":"Prognostic role of pre-treatment body composition parameters in patients undergoing first-line immunotherapy for metastatic renal cell carcinoma.","volume":"16","author":"Lee","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.3390\/cancers17172765","article-title":"The impact of body composition on outcomes in NSCLC patients treated with immune checkpoint inhibitors: a systematic review.","volume":"17","author":"Golban","year":"2025","journal-title":"Cancers"},{"key":"B151","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/1440-1681.13740","article-title":"Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.","volume":"50","author":"Fang","year":"2023","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1219929","DOI":"10.3389\/fimmu.2023.1219929","article-title":"Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors.","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.immuni.2024.07.013","article-title":"Macrophages dig into the obesity paradox in cancer.","volume":"57","author":"Nabel","year":"2024","journal-title":"Immunity"},{"key":"B154","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12943-025-02506-4","article-title":"Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression.","volume":"24","author":"Alishvandi","year":"2025","journal-title":"Mol Cancer"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1093\/ajcn\/nqac237","article-title":"Research gaps and opportunities in precision nutrition: an NIH workshop report.","volume":"116","author":"Lee","year":"2022","journal-title":"Am J Clin Nutr"},{"key":"B156","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00203-024-03843-6","article-title":"A new perspective on gut-lung axis affected through resident microbiome and their implications on immune response in respiratory diseases.","volume":"206","author":"Xu","year":"2024","journal-title":"Arch Microbiol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31547\/bct-2023-021","article-title":"Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy.","volume":"6","author":"Yoshida","year":"2023","journal-title":"Blood Cell Ther"},{"key":"B158","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1002\/cam4.4668","article-title":"The prognostic value of prognostic nutritional index in advanced cancer receiving PD-1\/L1 inhibitors: a meta-analysis.","volume":"11","author":"Li","year":"2022","journal-title":"Cancer Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/s12185-025-03935-z","article-title":"Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis.","volume":"121","author":"Jiang","year":"2025","journal-title":"Int J Hematol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1495460","DOI":"10.3389\/fimmu.2024.1495460","article-title":"Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study.","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.3390\/cancers17223675","article-title":"Prognostic significance of endocrine-related adverse events in patients with melanoma, non-small cell lung cancer and urothelial cancer after treatment with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"17","author":"Kopanos","year":"2025","journal-title":"Cancers"},{"key":"B162","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/cancers12040921","article-title":"The glasgow prognostic score at diagnosis is a predictor of clinical outcome in patients with multiple myeloma undergoing autologous haematopoietic stem cell transplantation.","volume":"12","author":"Witte","year":"2020","journal-title":"Cancers"},{"key":"B163","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.21037\/tlcr-21-710","article-title":"Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.","volume":"10","author":"Shi","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2217\/imt-2022-0133","article-title":"Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis.","volume":"14","author":"Tian","year":"2022","journal-title":"Immunotherapy"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-025-02732-z","article-title":"Risk factors for endocrinological immune-related adverse events in patients with renal cell carcinoma treated with immune checkpoint inhibitors.","author":"Marrano","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B166","doi-asserted-by":"publisher","first-page":"7400","DOI":"10.3390\/ijms26157400","article-title":"Mitochondrial metabolism in T-cell exhaustion.","volume":"26","author":"Li","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e002851","DOI":"10.1136\/jitc-2021-002851","article-title":"Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/cancers15041076","article-title":"Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer.","volume":"15","author":"Madeddu","year":"2023","journal-title":"Cancers"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1080729","DOI":"10.3389\/fonc.2022.1080729","article-title":"Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.","volume":"12","author":"Wasamoto","year":"2023","journal-title":"Front Oncol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1097\/JS9.0000000000000614","article-title":"Prognostic nutritional index with postoperative complications and 2-year mortality in hip fracture patients: an observational cohort study.","volume":"109","author":"Wang","year":"2023","journal-title":"Int J Surg"},{"key":"B171","doi-asserted-by":"publisher","first-page":"101603","DOI":"10.1016\/j.tranon.2022.101603","article-title":"Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation.","volume":"28","author":"Jin","year":"2023","journal-title":"Transl Oncol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1002\/cncr.34718","article-title":"Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD-1 therapy.","volume":"129","author":"Galus","year":"2023","journal-title":"Cancer"},{"key":"B173","doi-asserted-by":"publisher","first-page":"494.e1-10","DOI":"10.1016\/j.urolonc.2022.07.018","article-title":"Cachexia index in predicting outcomes among patients receiving immune checkpoint inhibitor treatment for metastatic renal cell carcinoma.","volume":"40","author":"Aslan","year":"2022","journal-title":"Urol Oncol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e006454","DOI":"10.1136\/jitc-2022-006454","article-title":"High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis.","volume":"11","author":"Jung","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B175","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41391-024-00870-8","article-title":"Body composition as a determinant of the therapeutic index with androgen signaling inhibition.","volume":"28","author":"Hahn","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1172931","DOI":"10.3389\/fimmu.2023.1172931","article-title":"The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy.","volume":"14","author":"Ganjoo","year":"2023","journal-title":"Front Immunol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12885-020-06921-2","article-title":"Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.","volume":"20","author":"Go","year":"2020","journal-title":"BMC Cancer"},{"key":"B178","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/CBM-210073","article-title":"Association between baseline controlling nutritional status score and clinical outcomes of patients with multiple myeloma.","volume":"32","author":"Zhou","year":"2021","journal-title":"Cancer Biomark"},{"key":"B179","doi-asserted-by":"publisher","first-page":"626812","DOI":"10.3389\/fimmu.2020.626812","article-title":"Iron metabolism in the tumor microenvironment: contributions of innate immune cells.","volume":"11","author":"Liang","year":"2021","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy.","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B181","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12876-025-04136-y","article-title":"A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e635","DOI":"10.1016\/S2352-3026(25)00117-6","article-title":"Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network.","volume":"12","author":"van de Donk","year":"2025","journal-title":"Lancet Haematol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.3389\/fimmu.2019.02965","article-title":"The intriguing history of cancer immunotherapy.","volume":"10","author":"Dobosz","year":"2019","journal-title":"Front Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1435480","DOI":"10.3389\/fonc.2024.1435480","article-title":"Lipids in the tumor microenvironment: immune modulation and metastasis.","volume":"14","author":"Pascual","year":"2024","journal-title":"Front Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion\u2019.","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.3390\/ijms21114030","article-title":"Manipulation of metabolic pathways and its consequences for anti-tumor immunity: a clinical perspective.","volume":"21","author":"Yang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B187","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.7150\/thno.117773","article-title":"Zinc-based nanomaterials in cancer therapy: mechanisms, applications, and future directions.","volume":"15","author":"Mu","year":"2025","journal-title":"Theranostics"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.immuni.2024.07.020","article-title":"Long-distance microbial mechanisms impacting cancer immunosurveillance.","volume":"57","author":"Zitvogel","year":"2024","journal-title":"Immunity"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1611829","DOI":"10.3389\/fnut.2025.1611829","article-title":"Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma.","volume":"12","author":"Chiriva-Internati","year":"2025","journal-title":"Front Nutr"},{"key":"B190","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2018.03.011","article-title":"Bone marrow adiposity and multiple myeloma.","volume":"118","author":"Morris","year":"2019","journal-title":"Bone."},{"key":"B191","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.3390\/cancers15215255","article-title":"Non-toxicological role of Aryl hydrocarbon receptor in obesity-associated multiple myeloma cell growth and survival.","volume":"15","author":"Diedrich","year":"2023","journal-title":"Cancers"},{"key":"B192","doi-asserted-by":"publisher","first-page":"86075","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy.","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"key":"B193","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4081\/oncol.2018.366","article-title":"Vitamin D and its receptor polymorphisms: new possible prognostic biomarkers in leukemias.","volume":"12","author":"Pezeshki","year":"2018","journal-title":"Oncol Rev"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1346211","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma.","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients.","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B196","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","article-title":"Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis.","volume":"70","author":"Guzman-Prado","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e9632","DOI":"10.1002\/ccr3.9632","article-title":"A novel intersection: cytomegalovirus gastritis following cemiplimab and talimogene laherparepvec in a patient with advanced cutaneous squamous cell carcinoma.","volume":"12","author":"Egoryan","year":"2024","journal-title":"Clin Case Rep"},{"key":"B198","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.3390\/ijms25147517","article-title":"Immunotherapy in breast cancer.","volume":"25","author":"Dvir","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B199","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s40478-025-02020-0","article-title":"Inflammation alters myeloid cell and oligodendroglial iron-handling in multiple sclerosis.","volume":"13","author":"Riedl","year":"2025","journal-title":"Acta Neuropathol Commun"},{"key":"B200","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s12094-024-03767-z","article-title":"Analysis of therapeutic effects and influencing factors of ICIs in lung-cancer patients.","volume":"27","author":"Luo","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B201","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.tips.2023.12.003","article-title":"Tumor iron homeostasis and immune regulation.","volume":"45","author":"Zhang","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.3390\/nu13061805","article-title":"The effect of dietary fibre on gut microbiota, lipid profile, and inflammatory markers in patients with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.","volume":"13","author":"Ojo","year":"2021","journal-title":"Nutrients"},{"key":"B203","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","article-title":"ESPEN guidelines on nutrition in cancer patients.","volume":"36","author":"Arends","year":"2017","journal-title":"Clin Nutr"},{"key":"B204","doi-asserted-by":"publisher","first-page":"e007235","DOI":"10.1136\/jitc-2023-007235","article-title":"Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.","volume":"11","author":"Akce","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B205","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2326-6066.CIR-16-0103","article-title":"Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia.","volume":"5","author":"Scharping","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B206","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/2159-8290.CD-25-0099","article-title":"MANIFEST: multiomic platform for cancer immunotherapy.","volume":"15","author":"Lim","year":"2025","journal-title":"Cancer Discov"},{"key":"B207","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1002\/mco2.387","article-title":"Progresses in biomarkers for cancer immunotherapy.","volume":"4","author":"Lin","year":"2023","journal-title":"MedComm"},{"key":"B208","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1186\/s12885-024-13343-x","article-title":"Clinical significance of the combined systemic immune-inflammatory index and prognostic nutritional index in predicting the prognosis of patients with extensive-stage small-cell lung cancer receiving immune-combination chemotherapy.","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B209","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.clnesp.2025.10.031","article-title":"Decreased appetite in cancer patients treated with immune checkpoint inhibitors (ICIs): the MOUSEION-012 systematic review and meta-analysis.","volume":"70","author":"Vitale","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"B210","doi-asserted-by":"publisher","first-page":"113392","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies.","volume":"144","author":"Sun","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B211","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/pharmaceutics16121582","article-title":"Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect.","volume":"16","author":"Feng","year":"2024","journal-title":"Pharmaceutics"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1080\/10408398.2025.2568606","article-title":"Glial cell nutrient sensing: mechanisms of nutrients regulating Alzheimer\u2019s pathogenesis and precision intervention.","author":"Yan","year":"2025","journal-title":"Crit Rev Food Sci Nutr"},{"key":"B213","doi-asserted-by":"publisher","first-page":"102135","DOI":"10.1016\/j.bbrep.2025.102135","article-title":"The HER2 target for designing novel multi-peptide vaccine against breast cancer using immunoinformatics and molecular dynamic simulation.","volume":"43","author":"Firuzpour","year":"2025","journal-title":"Biochem Biophys Rep"},{"key":"B214","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1515\/revneuro-2024-0097","article-title":"Nanocarriers in glioblastoma treatment: a neuroimmunological perspective.","volume":"36","author":"Firuzpour","year":"2025","journal-title":"Rev Neurosci"},{"key":"B215","doi-asserted-by":"publisher","first-page":"145203","DOI":"10.1016\/j.ijbiomac.2025.145203","article-title":"Unveiling the translational and therapeutic potential of small interfering RNA molecules in combating SARS-CoV-2: a review.","volume":"318","author":"Aram","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B216","doi-asserted-by":"publisher","first-page":"6661406","DOI":"10.1155\/2021\/6661406","article-title":"Current and future perspectives of PD-1\/PDL-1 blockade in cancer immunotherapy.","volume":"2021","author":"Makuku","year":"2021","journal-title":"J Immunol Res"},{"key":"B217","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/futurepharmacol5030043","article-title":"Assessing the pharmacological and pharmacogenomic data of PD-1\/PD-L1 inhibitors to enhance cancer immunotherapy outcomes in the clinical setting.","volume":"5","author":"Zervanos","year":"2025","journal-title":"Future Pharmacol."},{"key":"B218","doi-asserted-by":"publisher","first-page":"1458488","DOI":"10.3389\/fimmu.2024.1458488","article-title":"Biomarkers in the early stage of PD-1 inhibitor treatment have shown superior predictive capabilities for immune-related thyroid dysfunction.","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B219","doi-asserted-by":"publisher","first-page":"e88647","DOI":"10.7759\/cureus.88647","article-title":"Predictive biomarkers in cancer immunotherapy: a narrative review across selected solid tumors.","volume":"17","author":"Puntambekar","year":"2025","journal-title":"Cureus"},{"key":"B220","doi-asserted-by":"publisher","first-page":"3895","DOI":"10.1007\/s10238-023-01035-y","article-title":"Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta-analysis.","volume":"23","author":"Kou","year":"2023","journal-title":"Clin Exp Med"},{"key":"B221","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s40478-024-01895-9","article-title":"An immune scoring system predicts prognosis and immune characteristics in lung adenocarcinoma brain metastases by RNA sequencing.","volume":"12","author":"Xiao","year":"2024","journal-title":"Acta Neuropathol Commun"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/biom15091304","article-title":"A comprehensive oncological biomarker framework guiding precision medicine.","volume":"15","author":"Mokhtari","year":"2025","journal-title":"Biomolecules"},{"key":"B223","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/jitc-2023-SITC2023.0152","article-title":"152 Immuno-oncology protein biomarker panels provide greater biological insights and improved patient stratification.","volume":"11","author":"Rucevic","year":"2023","journal-title":"BMJ Specialist J."},{"key":"B224","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12935-024-03439-6","article-title":"Machine learning models for predicting of PD-1 treatment efficacy in pan-cancer patients based on routine hematologic and biochemical parameters.","volume":"24","author":"Yang","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B225","doi-asserted-by":"publisher","first-page":"104980","DOI":"10.1016\/j.critrevonc.2025.104980","article-title":"Predictive models for immune checkpoint inhibitor response in cancer: a review of current approaches and future directions.","volume":"216","author":"Oisakede","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B227","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/diagnostics15020226","article-title":"Machine-learning parsimonious prediction model for diagnostic screening of severe hematological adverse events in cancer patients treated with PD-1\/PD-L1 inhibitors: retrospective observational study by using the common data model.","volume":"15","author":"Park","year":"2025","journal-title":"Diagnostics"},{"key":"B228","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.34172\/bi.30984","article-title":"The role of artificial intelligence in enhancing breast cancer screening and diagnosis: a review of current advances.","volume":"15","author":"Firuzpour","year":"2025","journal-title":"Bioimpacts"},{"key":"B229","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.7150\/ijbs.78535","article-title":"The emerging role of super-enhancers as therapeutic targets in the digestive system tumors.","volume":"19","author":"Li","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B230","doi-asserted-by":"publisher","first-page":"109822","DOI":"10.1016\/j.abb.2023.109822","article-title":"M2 macrophage-derived exosomes induce angiogenesis and increase skin flap survival through HIF1AN\/HIF-1\u03b1\/VEGFA control.","volume":"751","author":"Luo","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"B231","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1093\/jnci\/92.12.994","article-title":"Diurnal cortisol rhythm as a predictor of breast cancer survival.","volume":"92","author":"Sephton","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B232","doi-asserted-by":"publisher","first-page":"818","DOI":"10.5306\/wjco.v15.i7.818","article-title":"Circadian rhythm disruption and endocrine-related tumors.","volume":"15","author":"Savvidis","year":"2024","journal-title":"World J Clin Oncol"},{"key":"B233","volume-title":"Multi-Omics and Mendelian Randomization Studies Unveiling Genetic and Molecular Mechanisms of Cancer Risk and Prognosis.","author":"Huang","year":"2024"},{"key":"B234","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1186\/s12885-022-10296-x","article-title":"Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.","volume":"22","author":"Caccialanza","year":"2022","journal-title":"BMC Cancer"},{"key":"B235","doi-asserted-by":"publisher","first-page":"1554048","DOI":"10.3389\/fimmu.2025.1554048","article-title":"Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"16","author":"Sz\u00e9les","year":"2025","journal-title":"Front Immunol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10753-023-01911-5","article-title":"SIRT6 protects against lipopolysaccharide-induced inflammation in human pulmonary lung microvascular endothelial cells.","volume":"47","author":"Wang","year":"2024","journal-title":"Inflammation."},{"key":"B237","doi-asserted-by":"publisher","first-page":"e70051","DOI":"10.1002\/imt2.70051","article-title":"Age-specific reference intervals for plasma amino acids and their associations with nutrient intake in the Chinese pediatric population.","volume":"4","author":"Wen","year":"2025","journal-title":"Imeta"},{"key":"B238","doi-asserted-by":"publisher","first-page":"974376","DOI":"10.3389\/fphar.2022.974376","article-title":"PD-1 inhibitor-based adverse events in solid tumors: a retrospective real-world study.","volume":"13","author":"Huang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00262-024-03869-1","article-title":"Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer.","volume":"74","author":"Ladjevardi","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"B240","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1002\/bcp.70167","article-title":"Randomization in phase II trials: no exemption based on sample size.","volume":"91","author":"Framke","year":"2025","journal-title":"Br J Clin Pharmacol"},{"key":"B241","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.21037\/jtd.2019.08.29","article-title":"Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?","volume":"12","author":"Lee","year":"2020","journal-title":"J Thorac Dis"},{"key":"B242","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41698-023-00351-6","article-title":"Racial and ethnic disparities in a real-world precision oncology data registry.","volume":"7","author":"Cheung","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"102035","DOI":"10.1016\/j.toxrep.2025.102035","article-title":"Advancing precision medicine: uncovering biomarkers and strategies to mitigate immune-related adverse events in immune checkpoint inhibitors therapy.","volume":"14","author":"Nityashree","year":"2025","journal-title":"Toxicol Rep"},{"key":"B244","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.3390\/cancers17193262","article-title":"Optimizing Anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring.","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers"},{"key":"B245","doi-asserted-by":"publisher","first-page":"1670598","DOI":"10.3389\/fnut.2025.1670598","article-title":"Nutritional strategies in supporting immune checkpoint inhibitor, PI3K inhibitor, and tyrosine kinase inhibitor cancer therapies.","volume":"12","author":"Fuller-Shavel","year":"2025","journal-title":"Front Nutr"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1753660\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:23:37Z","timestamp":1770269017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1753660\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":245,"alternative-id":["10.3389\/fnut.2025.1753660"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1753660","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1753660"}}